CORV Correvio Pharma Corporation

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13 A -16 or 15 d -16 of

The Securities Exchange Act of 1934

 

For the month of March 2017

 

C OMMISSION F ILE N umber . 000-29338

 

CARDIOME PHARMA CORP.

(Translation of registrant’s name into English)

 

1441 Creekside Drive, 6th floor

Vancouver, British Columbia, V6J 4S7, CANADA

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

 

Form 20-F ☐

Form 40-F ☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

  

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit		Description
99.1		Material Change Report Dated March 7, 2017
99.2		News Release dated March 7, 2017 - Cardiome Reports Fourth Quarter and full year 2016 Financial Results

 

Exhibits 99.1 and 99.2 of this report on Form 6-K is incorporated by reference into the Company’s registration statement on Form F-10 (File No. 333-193645) and registration statements on Form S-8 (File No. 333-199091 and File No. 333-199092).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	CARDIOME PHARMA CORP.
	(Registrant)
Date: March 7, 2017	By:	/s/ Jennifer Archibald
		Name: Jennifer Archibald
		Title: Chief Financial Officer